Get the Stockscreener App
76.06
3.72%
2.73
After Hours:
78.47
2.41
+3.17%
Bridgebio Pharma Inc stock is traded at $76.06, with a volume of 9.16M.
It is up +3.72% in the last 24 hours and down -1.02% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$73.33
Open:
$84.845
24h Volume:
9.16M
Relative Volume:
3.67
Market Cap:
$14.58B
Revenue:
$353.78M
Net Income/Loss:
$-805.69M
P/E Ratio:
-18.17
EPS:
-4.1869
Net Cash Flow:
$-597.61M
1W Performance:
+19.35%
1M Performance:
-1.02%
6M Performance:
+54.94%
1Y Performance:
+138.06%
1-Day Range:
$76.03
$84.94
1-Week Range:
$67.59
$84.94
52-Week Range:
$28.32
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
76.06 | 14.05B | 353.78M | -805.69M | -597.61M | -4.1869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-11-25 | Initiated | Bernstein | Outperform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jul-09-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
BridgeBio Confident Infigratinib Can Steal Achondroplasia Market Share - Citeline News & Insights
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares - MarketBeat
Dwarfism golden gate? Bridgebio’s infigratinib phase III hits - BioWorld MedTech
BridgeBio Announces Positive Phase 3 Achondroplasia Trial Results - TipRanks
Dwarfism meds 'miraculously' took kids who started at a low growth baseline to typical height velocity: BridgeBio Pharma CEO - Fox Business
BridgeBio Pharma shares rise on ‘compelling’ Phase 3 trial results for achondroplasia drug - Proactive financial news
BridgeBio reports positive phase 3 topline results for oral infigratinib - marketscreener.com
BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing - MedCity News
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week HighHere's What Happened - MarketBeat
BridgeBio's oral drug improves growth in children with dwarfism in late-stage study - marketscreener.com
BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally? - Stocktwits
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Bitget
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Benzinga
BridgeBio (BBIO) Surges on Positive Phase 3 Results for Infigrat - GuruFocus
BridgeBio gains on phase 3 dwarfism data - pharmaphorum
Positive Phase III top-line results for BridgeBio’s oral infigratinib - The Pharma Letter
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz
BridgeBio Pharma stock price target raised to $89 at Raymond James on positive trial data - Investing.com Canada
BridgeBio Pharma stock hits all-time high at 84.51 USD - Investing.com
BridgeBio Pharma Touts Strong Phase 3 PROPEL-3 Data for Oral Infigratinib in Achondroplasia - MarketBeat
BridgeBio posts trial win for dwarfism drug (BBIO:NASDAQ) - Seeking Alpha
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data By Investing.com - Investing.com Canada
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - The Manila Times
BridgeBio stock jumps after positive Phase 3 results for achondroplasia drug - Investing.com Canada
BridgeBio Pharma Reports Positive Topline Results from PROPEL 3 Study of Oral Infigratinib in Children with Achondroplasia - Quiver Quantitative
BBIO: Oral infigratinib delivers significant growth and proportionality benefits in achondroplasia - TradingView
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters
BridgeBio Pharma (BBIO) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Why (BBIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Candriam S.C.A. Invests $7.74 Million in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma supports LGMD Family Guide distribution at conference - Traders Union
Targets Report: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEARJuly 2025 Decliners & Fast Gain Stock Trading Tips - baoquankhu1.vn
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Buy the Dip on This Biotech Stock After Recent Fall - Finviz
BridgeBio Pharma (BBIO) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance
BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection (NASDAQ:BBIO) - Seeking Alpha
Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO), Bristol-Myers Squibb (BMY) and Qiagen (QGEN) - The Globe and Mail
BridgeBio (BBIO) tumbles 15%, mirrors marked bleed - MSN
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap UpHere's What Happened - MarketBeat
BridgeBio (BBIO) Tumbles 15%, Mirrors Marked Bleed - Finviz
BridgeBio Pharma Enters Oversold Territory (BBIO) - Nasdaq
WCM Investment Management LLC Sells 14,253 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. $BBIO Shares Acquired by Principal Financial Group Inc. - MarketBeat
Y Intercept Hong Kong Ltd Has $724,000 Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Eyeing a 20.55% Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Understanding Momentum Shifts in (BBIO) - Stock Traders Daily
Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT - MSN
BridgeBio Pharma, Inc. $BBIO Shares Acquired by Federated Hermes Inc. - MarketBeat
Movement Recap: Is BridgeBio Pharma Inc stock a value trapJuly 2025 Spike Watch & Comprehensive Market Scan Insights - baoquankhu1.vn
Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility - Yahoo Finance
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):